PDF Return
C. 90
To: Board of Supervisors
From: William Walker, M.D., Health Services Director
Date: July  12, 2016
The Seal of Contra Costa County, CA
Contra
Costa
County
Subject: Approve Purchase Order with Polymedco Cancer Diagnostics Products, LLC

APPROVE OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR RECOMMENDATION OF BOARD COMMITTEE

Action of Board On:   07/12/2016
APPROVED AS RECOMMENDED OTHER
Clerks Notes:

VOTE OF SUPERVISORS

AYE:
Candace Andersen, District II Supervisor
Mary N. Piepho, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor
ABSENT:
John Gioia, District I Supervisor
Contact: Anna Roth, 370-5101
cc: Tasha Scott     M Wilhelm     Margaret Harris    
I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED:     July  12, 2016
David Twa,
 
BY: , Deputy

 

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent, on behalf of the Health Services Department, to execute a Purchase Order with Polymedco Cancer Diagnostic Products, LLC. to add $360,000 for a new total of $480,000, for reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at the Contra Costa Regional Medical Center, with no change in the term from October 1, 2015 through September 30, 2019.

FISCAL IMPACT:

100% Funding is included in the Hospital Enterprise Fund I Budget.

BACKGROUND:

Polymedco’s OC-Auto Micro 80 Analyzer with FOBT-CHECKoc reagents is an automated immunochemical fecal occult blood testing system that detects human red cells only, with no interference from red meat, turnips, melons, aspirin, anti-inflammatory drugs and vitamin C. This improvement directs many more of the “right” patients to colonoscopy, leading to the earlier detection of polyps and colorectal cancer.

CONSEQUENCE OF NEGATIVE ACTION:

If this Purchase Order is not approved, the CCRMC Clinical Laboratory will not be able to perform patient testing for colorectal cancer.

CHILDREN'S IMPACT STATEMENT:

Not applicable.

AgendaQuick©2005 - 2024 Destiny Software Inc., All Rights Reserved